Stock·NASDAQ·Healthcare
Ionis Pharmaceuticals, Inc. (IONS)
- Market cap
- $7.33B
- Dividend yield
- 0.00%
- Street target
- $85.00median of 24 analysts
- 52-week range
- $42.08 $86.74
The short version
Where IONS stands today, in four lines, and what CleaRank Financial AI makes of it.
IONS at a glance
Ionis Pharmaceuticals, Inc. (IONS): Sell, 25/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($51.73 and $68.60).
- Earnings IONS beat estimates in 4 of its last 4 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $189.9M and bought $1.5M over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
Ionis Pharmaceuticals (IONS) is currently trading at $43.215, significantly below its 50-day and 200-day moving averages ($51.73 and $68.60), indicating a bearish technical trend.
The company's financial health is concerning, with a negative EPS of -3.62 and a substantial net loss margin of -64.66%. Revenue growth has also contracted by -40.7%, further pressuring the stock. Despite these fundamental weaknesses, Wall Street maintains a generally positive outlook, with a median analyst price target of $85.0, implying an upside of 96.7%. However, this optimism is sharply contrasted by significant insider selling, with over $189.9 million in sales versus only $1.5 million in purchases, leading to a 'Heavy Sell Signal' verdict. This divergence between analyst targets and insider actions warrants caution.
Only on CleaRank
Figures we compute ourselves from IONS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $43.22 is 16.5% below the 50-day simple moving average of $51.73.Price above its 200-day average ›
The price is 37.0% below the 200-day simple moving average of $68.60.50-day average above the 200-day ›
The 50-day average ($51.73) is 24.6% below the 200-day average ($68.60), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 3% of its 52-week range, between $42.08 and $86.74.
IONS share price
Pick a period: each tab shows how far IONS has moved over it, to the last close.
Today's trading
Where IONS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 8.39 is 146.7% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-565.2M on revenue of $874.1M, a net margin of -64.7%.Beat estimates in most recent reports ›
IONS beat the EPS estimate in 4 of its last 4 reports.
Key statistics
The headline figures for IONS.
As of October 16, 2026, IONS trades at $43.22, with a market value of $7.33B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of IONS's valuation, growth and risks.
Ionis Pharmaceuticals (IONS) exhibits concerning fundamental metrics, with a negative EPS of -3.62 and a substantial net profit margin of -64.66%.
The company's return on equity is a significantly negative -105.50%, and its price-to-sales ratio stands at 8.39, which is considerably higher than the sector median of 3.4. The debt-to-equity ratio is also high at 4.98, exceeding the sector average. Despite these challenges, Wall Street analysts project revenue growth of +18.00% for the next quarter and +48.00% for the next year, which contrasts sharply with the current -40.7% revenue growth. The company's valuation appears stretched given its profitability issues and high debt levels when compared to sector averages.
IONS against the Healthcare sector
How IONS compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, IONS trades at 8.39x, +147% versus the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, IONS has gained 31.1% against a gain of 28.3% for XLV.
Performance against XLV
IONS and the Healthcare sector fund over the same days.
Revenue and earnings
How much IONS sells, and how much of it becomes profit.
Revenue growth: Revenue grew 33.8% in FY2025 to $944M, from $705M a year earlier.
Profit margin: The net margin was -40.4% in FY2025, up from -64.4% the year before.
Profitable: IONS lost $381M in FY2025.
Earnings reality check
Did IONS beat what analysts expected, and how did the stock react?
Earnings record: IONS beat the analyst estimate in 4 of the last 4 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 29, 2025after close | -$1.05 | -$0.61 | +41.90% | +3.19% | +3.90% |
| Jul 30, 2025after close | $0.16 | $0.85 | +431.25% | -0.90% | -6.18% |
| Apr 30, 2025after close | -$1.03 | -$0.92 | +10.68% | +3.26% | +7.68% |
| Feb 19, 2025after close | -$0.84 | -$0.43 | +48.81% | +2.77% | -0.16% |
Reports after October 29, 2025 are not yet in our data.
As of October 16, 2026, IONS has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 1 of those beats; its most recent report in our data, on October 29, 2025, came in 41.90% above the estimate and the stock moved +3.19% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 38.4, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 38.4 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of IONS
The score, the reasoning behind it, and what could move the price next.
Ionis Pharmaceuticals (IONS) is trading below its 50-day SMA of $51.73 and its 200-day SMA of $68.60, signaling a bearish trend.
The 14-day RSI is at 38.39, indicating bearish momentum, and the MACD is at -2.298, further reinforcing the negative technical picture. The stock's current price of $43.215 is also below its 20-day EMA of $45.17. Key support levels are not clearly defined given the downward trend, but the current price action suggests further downside potential. The overall chart structure points towards continued weakness unless a significant catalyst emerges.
Positive Analyst Sentiment and Price Targets ›
Despite current challenges, 24 analysts maintain a 'Buy' consensus with a median price target of $85.0, suggesting potential for significant upside if the company can execute its turnaround strategy.
Source: Wall Street AnalystsRecent Earnings Beat (EPS -0.61 vs -1.05 Estimate) ›
The latest reported earnings beat expectations, showing a positive surprise of 41.9%, which could signal improving operational efficiency or successful cost management.
Source: Earnings Report
Negative Revenue Growth of -40.7% ›
The company's revenue has contracted significantly, raising concerns about its ability to generate sales and fund operations, especially given its current loss-making status.
Source: Company Financials
- Given the heavy insider selling exceeding $189.9 million, investors should exercise extreme caution and monitor future insider transactions closely for any signs of changing sentiment.
- The stock is trading below its key moving averages (50-day SMA, 200-day SMA, 20-day EMA) and shows bearish momentum on the 14-day RSI, suggesting potential for further price declines.
- With a high debt-to-equity ratio of 4.98 and persistent net losses, risk management is paramount. Consider position sizing carefully and setting appropriate stop-loss levels.
Technical indicators
Momentum and trend for IONS, from its daily closes.
As of October 16, 2026, with IONS at $43.22, its 14-day RSI is 38.4 (showing bearish momentum without being oversold), its 50-day simple moving average is $51.73 and its 200-day is $68.60.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What IONS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, IONS's 1-year correlation of daily returns is +0.23 with S&P 500 (SPY), +0.18 with Nasdaq 100 (QQQ), +0.01 with Bitcoin (BTC) and +0.12 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
19 of 24 analysts rate it a buy or strong buy, 5 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $85.00 is 96.7% above the price.More buy ratings than three months ago ›
19 of 24 rate it a buy now, against 19 of 23 three months ago.
IONS Wall Street View
12-month price targets
The price, $43.22, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | Reiterates | Buy |
| Sep 22, 2026 | JP Morgan | Maintains | Overweight |
| Sep 15, 2026 | Guggenheim | Maintains | Buy |
| Sep 9, 2026 | Barclays | Maintains | Overweight |
| Sep 8, 2026 | Morgan Stanley | Maintains | Overweight |
| Sep 8, 2026 | Goldman Sachs | Maintains | Neutral |
As of October 16, 2026, 24 Wall Street analysts cover IONS: 19 rate it a buy or strong buy, 5 a hold and 0 a sell or strong sell. Their 12-month price targets range from $54.00 to $105.00, with a median of $85.00, 96.7% above the price of $43.22.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
IONS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from IONS's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much IONS tends to move, against the market and on its own.
The long record
IONS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.94% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 70.0%, from April 2019 to April 2025, regained by February 2026.Most 1-year holds ended higher ›
53% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $15,282, against $42,525 in the S&P 500 (SPY).
IONS Drawdowns & Recovery
As of October 16, 2026, IONS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -70.0% (April 2019 to April 2025); it regained that peak by February 2026, 10 months after the low, and 53% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into IONS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: IONS trailed the S&P 500 over this period: $15,282 against $42,525.
A $10,000 investment in IONS in October 2016 would be worth about $15,282 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to IONS, and which have not.
Strongest month, November: an average of +11.33%, up in 7 of 10 years.
Weakest month, February: an average of -2.85%, up in 4 of 10 years.
This month, October: has averaged +0.47%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, IONS's strongest calendar month has been November (average +11.33%, up in 7 of 10 years) and its weakest February (average -2.85%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in IONS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IONS today could grow to about $16,908 by 2036 in the base case, with a 90th-percentile outcome near $107,558 and a 10th-percentile outcome around $2,658. Projections are statistical simulations, not guarantees.
IONS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $53.32 for IONS by 2030 in the base case, from $43.22 today (1.2x over 4 years). The 10th-percentile path ends near $16.54. These are outcomes of a Monte Carlo simulation run on IONS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $25.37 | $45.55 | $81.76 | |
| 2028 | $20.98 | $48.00 | $110 | |
| 2029 | $18.36 | $50.59 | $139 | |
| 2030 | $16.54 | $53.32 | $172 | |
| 2031 | $15.19 | $56.19 | $208 |
Method: a lognormal simulation of IONS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
IONS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.5M on the open market and sold $189.9M.
As of October 16, 2026, IONS insiders reported 107 open-market sales worth $189.9M and 2 open-market purchases worth $1.5M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 31, 2026 | Michael Reuben Hayden
Director
|
Buy | 20.0K | $1.1M |
| Jul 15, 2026 | Spencer R Berthelsen
Director
|
Grant | 5.2K | - |
| Jul 15, 2026 | Joan E Herman
Director
|
Grant | 5.2K | - |
| Jul 7, 2026 | C Frank Bennett
Officer
|
Sell | 20.5K | $1.7M |
| Jul 7, 2026 | Allene M. Diaz
Director
|
Sell | 10.1K | $863.6K |
| Jul 7, 2026 | Holly B Kordasiewicz
Officer
|
Sell | 362 | $30.5K |
| Jul 7, 2026 | Allene M. Diaz
Director
|
Option | 10.1K | $476.3K |
| Jul 1, 2026 | Joseph S Klein III
Director
|
Sell | 11.5K | $910.4K |
| Jul 1, 2026 | Joseph S Klein III
Director
|
Option | 11.5K | $460.0K |
| Jun 26, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 85.6K | $6.8M |
| Jun 26, 2026 | Eugene Schneider
Officer
|
Sell | 26.0K | $2.1M |
| Jun 26, 2026 | Joseph Baroldi
Officer
|
Sell | 5.6K | $451.7K |
| Jun 26, 2026 | Patrick R O'Neil
General Counsel
|
Sell | 3.1K | $245.5K |
| Jun 26, 2026 | Joseph Baroldi
Officer
|
Option | 5.6K | $277.2K |
| Jun 26, 2026 | Brett P Monia
Chief Executive Officer
|
Option | 85.6K | $4.0M |
| Jun 26, 2026 | Eugene Schneider
Officer
|
Option | 26.0K | $1.6M |
| Jun 25, 2026 | Eric E Swayze
Officer
|
Sell | 10.6K | $839.5K |
| Jun 15, 2026 | Spencer R Berthelsen
Director
|
Sell | 8.0K | $587.9K |
| Jun 15, 2026 | Spencer R Berthelsen
Director
|
Option | 8.0K | $195.4K |
| Jun 12, 2026 | Holly B Kordasiewicz
Officer
|
Sell | 60.8K | $4.5M |
| Jun 12, 2026 | Holly B Kordasiewicz
Officer
|
Option | 60.8K | $3.3M |
| Jun 1, 2026 | Spencer R Berthelsen
Director
|
Sell | 8.0K | $605.4K |
| Jun 1, 2026 | Spencer R Berthelsen
Director
|
Option | 8.0K | $195.4K |
| May 14, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 4.5K | $356.0K |
| May 14, 2026 | Brett P Monia
Chief Executive Officer
|
Option | 4.5K | $147.9K |
| May 4, 2026 | Joseph Loscalzo
Director
|
Sell | 77.3K | $5.8M |
| May 4, 2026 | Joseph Loscalzo
Director
|
Option | 77.3K | $3.8M |
| May 1, 2026 | Joseph S Klein III
Director
|
Sell | 10.1K | $743.2K |
| May 1, 2026 | Joseph S Klein III
Director
|
Option | 10.1K | $476.3K |
| Apr 28, 2026 | Joseph Baroldi
Officer
|
Sell | 1.6K | $116.7K |
| Apr 16, 2026 | Joseph Baroldi
Officer
|
Sell | 5.6K | $419.0K |
| Apr 16, 2026 | Kyle Jenne
Officer
|
Sell | 4.9K | $368.5K |
| Apr 16, 2026 | Brian Birchler
Officer
|
Sell | 973 | $73.0K |
| Apr 15, 2026 | B Lynne Parshall
Director
|
Sell | 5.0K | $381.4K |
| Apr 15, 2026 | Joseph Baroldi
Officer
|
Grant | 10.8K | - |
| Apr 15, 2026 | Brian Birchler
Officer
|
Grant | 1.9K | - |
| Apr 15, 2026 | Kyle Jenne
Officer
|
Grant | 12.2K | - |
| Apr 2, 2026 | Shannon L Devers
Officer
|
Sell | 6.2K | $458.6K |
| Apr 1, 2026 | Joseph S Klein III
Director
|
Sell | 22.3K | $1.7M |
| Apr 1, 2026 | Joseph S Klein III
Director
|
Option | 22.3K | $880.7K |
| Mar 19, 2026 | Eugene Schneider
Officer
|
Sell | 5.8K | $412.5K |
| Mar 17, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Sell | 225.2K | $16.3M |
| Mar 16, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Option | 175.0K | $9.0M |
| Mar 10, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 160.8K | $12.1M |
| Mar 10, 2026 | Kyle Jenne
Officer
|
Sell | 37.3K | $2.8M |
| Mar 10, 2026 | Kyle Jenne
Officer
|
Option | 37.3K | $1.7M |
| Mar 10, 2026 | Brett P Monia
Chief Executive Officer
|
Option | 148.5K | $9.0M |
| Mar 9, 2026 | Patrick R O'Neil
General Counsel
|
Sell | 10.1K | $763.7K |
| Mar 4, 2026 | Joseph Baroldi
Officer
|
Sell | 6.7K | $531.0K |
| Mar 4, 2026 | Joseph Loscalzo
Director
|
Sell | 1.0K | $82.8K |
| Mar 4, 2026 | Joseph Baroldi
Officer
|
Option | 2.1K | $95.3K |
| Mar 4, 2026 | Joseph Loscalzo
Director
|
Option | 1.0K | $39.3K |
| Mar 3, 2026 | C Frank Bennett
Officer
|
Sell | 85.1K | $6.7M |
| Mar 3, 2026 | Allene M. Diaz
Director
|
Sell | 54.9K | $4.4M |
| Mar 3, 2026 | Joseph S Klein III
Director
|
Sell | 21.3K | $1.7M |
| Mar 3, 2026 | Shannon L Devers
Officer
|
Sell | 20.1K | $1.6M |
| Mar 3, 2026 | C Frank Bennett
Officer
|
Option | 65.1K | $3.5M |
| Mar 3, 2026 | Shannon L Devers
Officer
|
Option | 20.1K | $723.3K |
| Mar 3, 2026 | Allene M. Diaz
Director
|
Option | 40.3K | $1.6M |
| Mar 3, 2026 | Joseph S Klein III
Director
|
Option | 16.0K | $652.1K |
| Feb 13, 2026 | Eric E Swayze
Officer
|
Sell | 15.6K | $1.3M |
| Feb 11, 2026 | B Lynne Parshall
Director
|
Sell | 5.0K | $413.6K |
| Feb 6, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 29.4K | $2.5M |
| Feb 2, 2026 | C Frank Bennett
Officer
|
Sell | 85.1K | $7.1M |
| Feb 2, 2026 | C Frank Bennett
Officer
|
Option | 65.1K | $3.5M |
| Jan 30, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 63.0K | $5.2M |
| Jan 30, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Sell | 7.0K | $581.7K |
| Jan 30, 2026 | Patrick R O'Neil
General Counsel
|
Sell | 6.2K | $516.2K |
| Jan 30, 2026 | Eugene Schneider
Officer
|
Sell | 6.2K | $515.6K |
| Jan 30, 2026 | Brian Birchler
Officer
|
Sell | 6.2K | $513.0K |
| Jan 30, 2026 | Eric E Swayze
Officer
|
Sell | 6.2K | $512.4K |
| Jan 30, 2026 | C Frank Bennett
Officer
|
Sell | 5.9K | $488.1K |
| Jan 30, 2026 | Joseph Baroldi
Officer
|
Sell | 5.3K | $439.4K |
| Jan 29, 2026 | Joseph Baroldi
Officer
|
Grant | 10.3K | - |
| Jan 29, 2026 | C Frank Bennett
Officer
|
Grant | 11.4K | - |
| Jan 29, 2026 | Brian Birchler
Officer
|
Grant | 12.0K | - |
| Jan 29, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Grant | 13.6K | - |
| Jan 29, 2026 | Brett P Monia
Chief Executive Officer
|
Grant | 122.2K | - |
| Jan 29, 2026 | Patrick R O'Neil
General Counsel
|
Grant | 12.0K | - |
| Jan 29, 2026 | Eugene Schneider
Officer
|
Grant | 12.0K | - |
| Jan 29, 2026 | Eric E Swayze
Officer
|
Grant | 12.0K | - |
| Jan 22, 2026 | Shannon L Devers
Officer
|
Sell | 4.0K | $323.5K |
| Jan 16, 2026 | Brett P Monia
Chief Executive Officer
|
Sell | 44.0K | $3.3M |
| Jan 16, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Sell | 12.9K | $972.0K |
| Jan 16, 2026 | Eric E Swayze
Officer
|
Sell | 9.9K | $748.4K |
| Jan 16, 2026 | Eugene Schneider
Officer
|
Sell | 9.3K | $703.1K |
| Jan 16, 2026 | Patrick R O'Neil
General Counsel
|
Sell | 9.2K | $697.0K |
| Jan 16, 2026 | C Frank Bennett
Officer
|
Sell | 9.0K | $674.6K |
| Jan 16, 2026 | Brian Birchler
Officer
|
Sell | 8.5K | $636.9K |
| Jan 16, 2026 | Shannon L Devers
Officer
|
Sell | 8.4K | $634.4K |
| Jan 16, 2026 | Joseph Baroldi
Officer
|
Sell | 8.1K | $610.3K |
| Jan 16, 2026 | Holly B Kordasiewicz
Officer
|
Sell | 4.1K | $313.3K |
| Jan 16, 2026 | Kyle Jenne
Officer
|
Sell | 1.8K | $138.5K |
| Jan 15, 2026 | Joseph Baroldi
Officer
|
Grant | 19.9K | - |
| Jan 15, 2026 | C Frank Bennett
Officer
|
Grant | 21.1K | - |
| Jan 15, 2026 | Brian Birchler
Officer
|
Grant | 20.1K | - |
| Jan 15, 2026 | Shannon L Devers
Officer
|
Grant | 17.4K | - |
| Jan 15, 2026 | Elizabeth L Hougen
Chief Financial Officer
|
Grant | 28.7K | - |
| Jan 15, 2026 | Kyle Jenne
Officer
|
Grant | 7.0K | - |
| Jan 15, 2026 | Holly B Kordasiewicz
Officer
|
Grant | 11.1K | - |
| Jan 15, 2026 | Brett P Monia
Chief Executive Officer
|
Grant | 89.1K | - |
| Jan 15, 2026 | Patrick R O'Neil
General Counsel
|
Grant | 21.5K | - |
| Jan 15, 2026 | Eugene Schneider
Officer
|
Grant | 21.7K | - |
| Jan 15, 2026 | Eric E Swayze
Officer
|
Grant | 21.5K | - |
| Jan 15, 2026 | Michael J. Yang
Director
|
Grant | 1.9K | - |
| Jan 7, 2026 | Shannon L Devers
Officer
|
Sell | 44.2K | $3.8M |
| Jan 7, 2026 | Shannon L Devers
Officer
|
Option | 44.2K | $2.3M |
| Jan 2, 2026 | Eric E Swayze
Officer
|
Sell | 23.5K | $1.9M |
| Jan 2, 2026 | Eric E Swayze
Officer
|
Option | 23.5K | $1.4M |
| Dec 1, 2025 | Joseph H. Wender
Director
|
Sell | 28.0K | $2.3M |
| Nov 25, 2025 | Shannon L Devers
Officer
|
Sell | 16.8K | $1.4M |
| Nov 25, 2025 | Joseph S Klein III
Director
|
Sell | 12.0K | $960.0K |
| Nov 25, 2025 | Shannon L Devers
Officer
|
Option | 16.8K | $902.1K |
| Nov 25, 2025 | Joseph S Klein III
Director
|
Grant | 12.0K | - |
| Nov 19, 2025 | Joan E Herman
Director
|
Sell | 44.0K | $3.2M |
| Nov 19, 2025 | Joan E Herman
Director
|
Option | 44.0K | $2.5M |
| Nov 18, 2025 | Joseph H. Wender
Director
|
Option | 16.0K | $390.7K |
| Nov 6, 2025 | Richard S Geary
Officer
|
Sell | 34.6K | $2.6M |
| Nov 6, 2025 | Brian Birchler
Officer
|
Sell | 8.0K | $609.4K |
| Nov 6, 2025 | Richard S Geary
Officer
|
Option | 34.6K | $2.0M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.